BC
ALNY icon

Brookfield Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brookfield Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,010
Closed -$3.65M – 617
2022
Q2 		$3.65M Buy
+25,010
New +$3.55M 0.02% 311
2022
Q1 		– Sell
-24,352
Closed -$4.13M – 605
2021
Q4 		$4.13M Buy
+24,352
New +$4.53M 0.02% 243

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brookfield Corp's ALNY Position: Q3 2022 in Review

Brookfield Corp sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 25,010 shares — an estimated $3.65M sold.

Brookfield Corp first reported a position in ALNY in Q4 2021 and held it in 2 quarters. The position peaked at $4.13M in Q4 2021. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Brookfield Corp reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 25,010 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $3.65M.
  • Brookfield Corp first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Brookfield Corp's Alnylam Pharmaceuticals position peaked at $4.13M in Q4 2021.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.